Venetoclax-Azacitidine With Chidamide and CAG for Older AML Patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old
- You have been newly diagnosed with acute myeloid leukemia (AML)
- Your liver and kidney function are adequate (certain blood test levels must be within acceptable ranges)
- You do not have an active infection or severe mental health condition
- You are able to care for yourself with minimal help (ECOG performance status 0–3)
- You are not pregnant, breastfeeding, or a heavy smoker or drinker
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a triple combination of CHG (a chemotherapy regimen), venetoclax, and azacytidine for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet had any treatment. The goal is to see if this combination works better than standard care.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Hear when a new Newly Diagnosed Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.